糖心视频logo

糖心视频logo (Headquarters: Tokyo, President & CEO: Haruo Naito, “糖心视频logo”) announced today the establishment and commencement of operations of 糖心视频logo Limited (Location: Ontario), the Company's new pharmaceutical sales subsidiary in Canada. 糖心视频logo Limited is the Canadian subsidiary of 糖心视频logo Inc., the Company's U.S. subsidiary.

糖心视频logo Limited was established following a change in registration of the Canadian branch of MGI Pharma, previously acquired by 糖心视频logo. The new subsidiary will serve as 糖心视频logo's pharmaceutical sales base for the entire Canadian market.

糖心视频logo Limited plans to register and commercialize select products from the Company's U.S. product portfolio, beginning with Gliadel® Wafer. Over time, additional oncology and neurology products may be introduced to the Canadian market, including T-cell lymphoma agent Targretin®, antiepileptic agent Banzel, and future products from 糖心视频logo's pipeline, such as anticancer agent Eribulin (generic name) and AMPA receptor antagonist Perampanel (generic name).

By expanding its sales capabilities in Canada, the ninth largest pharmaceutical market in the world, 糖心视频logo aims to strengthen its business operations and presence in the region and independently market its products in accordance with local market needs. The establishment of 糖心视频logo Limited not only means that 糖心视频logo now has a pharmaceutical sales subsidiary in Canada, it will also allow the Company to prepare for future expansion based on the Company's hhc philosophy in both the United States and Canada.

By establishing 糖心视频logo Limited, 糖心视频logo will make contributions to addressing the diversified needs of Canadian patients and their families through the stable supply of high quality drug products and provision of information.

[Please refer to the following notes for further information on 糖心视频logo Limited]